Theralink Technologies Inc Financials
This page shows Theralink Technologies Inc (THER) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Theralink’s high-margin but tiny revenue base is being funded by external financing rather than operating self-sufficiency.
From FY2021 to FY2023, revenue moved from$506K to$607K . Over the same span, operating cash burn stayed near-$5M and financing inflows reached$6.5M , showing that added sales have not yet reduced the cash required to operate.
FY2023 gross margin of
Cash use is coming mostly from operations, not from heavy reinvestment: FY2023 capex was only
Financial Health Signals
Based on FY2023 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Theralink Technologies Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Theralink Technologies Inc has an operating margin of -1479.8%, meaning the company retains $-1480 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -2049.6% the prior year.
Theralink Technologies Inc's revenue grew 6.8% year-over-year to $607K, a solid pace of expansion. This earns a growth score of 49/100.
Theralink Technologies Inc's current ratio of 0.03 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
While Theralink Technologies Inc generated -$5.8M in operating cash flow, capex of $163K consumed most of it, leaving -$5.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Theralink Technologies Inc passes 2 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Key Financial Metrics
Earnings & Revenue
Theralink Technologies Inc generated $607K in revenue in fiscal year 2023. This represents an increase of 6.8% from the prior year.
Theralink Technologies Inc's EBITDA was -$8.8M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 23.3% from the prior year.
Theralink Technologies Inc earned $-0.01 per diluted share (EPS) in fiscal year 2023.
Cash & Balance Sheet
Theralink Technologies Inc generated -$5.9M in free cash flow in fiscal year 2023, representing cash available after capex. This represents a decrease of 7.6% from the prior year.
Theralink Technologies Inc held $997K in cash against $0 in long-term debt as of fiscal year 2023.
Theralink Technologies Inc had 6.15B shares outstanding in fiscal year 2023. This represents an increase of 0.0% from the prior year.
Margins & Returns
Theralink Technologies Inc's gross margin was 79.2% in fiscal year 2023, indicating the percentage of revenue retained after direct costs. This is up 18.8 percentage points from the prior year.
Theralink Technologies Inc's operating margin was -1479.8% in fiscal year 2023, reflecting core business profitability. This is up 569.8 percentage points from the prior year.
Capital Allocation
Theralink Technologies Inc invested $163K in capex in fiscal year 2023, funding long-term assets and infrastructure. This represents an increase of 24.1% from the prior year.
THER Income Statement
| Metric | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84K-53.2% | $179K-11.4% | $202K+19.2% | $170K+207.1% | $55K-81.9% | $305K+85.9% | $164K+742.1% | $20K |
| Cost of Revenue | $53K+32.7% | $40K-20.3% | $50K+97.0% | $25K+135.0% | $11K-83.3% | $65K-35.0% | $99K+479.1% | $17K |
| Gross Profit | $31K-77.8% | $139K-8.5% | $152K+5.5% | $144K+224.6% | $44K-81.5% | $241K+271.6% | $65K+2690.0% | $2K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $0+100.0% | -$640K-287.0% | $342K-19.0% | $423K | $0+100.0% | -$1.5M-367.1% | $545K+4.2% | $523K |
| Operating Income | -$1.5M+33.8% | -$2.3M-21.5% | -$1.9M+10.5% | -$2.1M+16.7% | -$2.6M+64.8% | -$7.3M-431.9% | -$1.4M+11.8% | -$1.6M |
| Interest Expense | $4.6M | N/A | $5.1M+3.4% | $4.9M+164.9% | $1.8M+406.3% | $365K+11.6% | $327K+22.4% | $267K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | $4.5M+152.5% | -$8.6M | N/A | -$7.7M-349.7% | -$1.7M+6.9% | -$1.8M |
| EPS (Diluted) | $0.00 | N/A | $0.00 | N/A | $-0.01 | N/A | $0.00 | N/A |
THER Balance Sheet
| Metric | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.8M-37.4% | $2.8M+65.2% | $1.7M-23.2% | $2.2M-30.8% | $3.2M+25.0% | $2.6M+8.5% | $2.4M-14.5% | $2.8M |
| Current Assets | $257K-79.7% | $1.3M+458.6% | $226K-49.1% | $444K-67.8% | $1.4M+113.1% | $647K+42.5% | $454K-48.6% | $884K |
| Cash & Equivalents | $24K-97.6% | $997K+3875.8% | $25K-87.9% | $208K-81.6% | $1.1M+187.4% | $393K+213.7% | $125K-72.0% | $447K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $46K+91.5% | $24K+59.4% | $15K-63.1% | $41K-15.9% | $48K+50.3% | $32K-70.6% | $109K-20.2% | $137K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $58.9M+43.8% | $41.0M-16.8% | $49.2M-9.8% | $54.6M+14.8% | $47.6M+405.9% | $9.4M+25.2% | $7.5M+11.7% | $6.7M |
| Current Liabilities | $57.8M+45.1% | $39.8M-17.2% | $48.1M-10.0% | $53.4M+15.2% | $46.4M+1242.0% | $3.5M+69.6% | $2.0M-7.7% | $2.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | $250K | N/A | N/A | N/A |
| Total Equity | -$57.1M-49.9% | -$38.1M+19.8% | -$47.5M+9.2% | -$52.3M-18.1% | -$44.3M-551.4% | -$6.8M-33.0% | -$5.1M-30.5% | -$3.9M |
| Retained Earnings | -$112.8M-20.3% | -$93.8M+9.3% | -$103.4M+4.2% | -$107.9M-8.6% | -$99.3M-58.1% | -$62.8M-14.1% | -$55.1M-3.3% | -$53.3M |
THER Cash Flow Statement
| Metric | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$963K+36.0% | -$1.5M-99.8% | -$753K+56.8% | -$1.7M+2.0% | -$1.8M-91.2% | -$929K+43.4% | -$1.6M-23.9% | -$1.3M |
| Capital Expenditures | N/A | $155K | $0 | $0-100.0% | $8K-81.6% | $43K-48.0% | $83K | N/A |
| Free Cash Flow | N/A | -$1.7M-120.4% | -$753K+56.8% | -$1.7M+2.4% | -$1.8M-83.5% | -$972K+43.6% | -$1.7M | N/A |
| Investing Cash Flow | N/A | -$155K | $0 | $0+100.0% | -$8K+81.6% | -$43K+48.0% | -$83K | N/A |
| Financing Cash Flow | -$11K-100.4% | $2.6M+361.7% | $570K-30.4% | $819K-67.5% | $2.5M+103.3% | $1.2M-11.5% | $1.4M+3.0% | $1.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
THER Financial Ratios
| Metric | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 36.9%-40.8pp | 77.7%+2.5pp | 75.3%-9.8pp | 85.0%+4.6pp | 80.4%+1.6pp | 78.8%+39.4pp | 39.4%+27.5pp | 11.9% |
| Operating Margin | -1842.9%-540.0pp | -1302.9%-353.6pp | -949.3%+314.8pp | -1264.1%+3394.2pp | -4658.3%-2259.5pp | -2398.7%-1560.6pp | -838.1%+7163.4pp | -8001.5% |
| Net Margin | N/A | N/A | 2222.8%+7268.2pp | -5045.4% | N/A | -2517.8%-1477.3pp | -1040.6%+8374.8pp | -9415.4% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | 260.8%+642.0pp | -381.2% | N/A | -295.7%-224.3pp | -71.4%-5.8pp | -65.5% |
| Current Ratio | 0.00-0.0 | 0.03+0.0 | 0.000.0 | 0.01-0.0 | 0.03-0.2 | 0.19-0.0 | 0.22-0.2 | 0.40 |
| Debt-to-Equity | -1.03+0.0 | -1.07-0.0 | -1.040.0 | -1.04-1.0 | -0.01+1.4 | -1.38+0.1 | -1.47+0.2 | -1.72 |
| FCF Margin | N/A | -925.7%-553.8pp | -371.9%+653.9pp | -1025.8%+2201.2pp | -3226.9%-2908.3pp | -318.6%+731.5pp | -1050.1% | N/A |
Note: Shareholder equity is negative (-$38.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Theralink Technologies Inc's annual revenue?
Theralink Technologies Inc (THER) reported $607K in total revenue for fiscal year 2023. This represents a 6.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Theralink Technologies Inc's revenue growing?
Theralink Technologies Inc (THER) revenue grew by 6.8% year-over-year, from $568K to $607K in fiscal year 2023.
What is Theralink Technologies Inc's EBITDA?
Theralink Technologies Inc (THER) had EBITDA of -$8.8M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
What is Theralink Technologies Inc's gross margin?
Theralink Technologies Inc (THER) had a gross margin of 79.2% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.
What is Theralink Technologies Inc's operating margin?
Theralink Technologies Inc (THER) had an operating margin of -1479.8% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.
What is Theralink Technologies Inc's free cash flow?
Theralink Technologies Inc (THER) generated -$5.9M in free cash flow during fiscal year 2023. This represents a -7.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Theralink Technologies Inc's operating cash flow?
Theralink Technologies Inc (THER) generated -$5.8M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Theralink Technologies Inc's total assets?
Theralink Technologies Inc (THER) had $2.8M in total assets as of fiscal year 2023, including both current and long-term assets.
What are Theralink Technologies Inc's capital expenditures?
Theralink Technologies Inc (THER) invested $163K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
What is Theralink Technologies Inc's current ratio?
Theralink Technologies Inc (THER) had a current ratio of 0.03 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is Theralink Technologies Inc's debt-to-equity ratio?
Theralink Technologies Inc (THER) had a debt-to-equity ratio of -1.07 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Theralink Technologies Inc's cash runway?
Based on fiscal year 2023 data, Theralink Technologies Inc (THER) had $997K in cash against an annual operating cash burn of $5.8M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Theralink Technologies Inc's debt-to-equity ratio negative or unusual?
Theralink Technologies Inc (THER) has negative shareholder equity of -$38.1M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Theralink Technologies Inc's Piotroski F-Score?
Theralink Technologies Inc (THER) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
How financially healthy is Theralink Technologies Inc?
Theralink Technologies Inc (THER) scores 8 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.